Patient description: A 34 year old man comes to the clinic complaining of dizziness and severe diarrhea since yesterday. He has returned from an international trip few days ago and was living in a camp in Sudan for a month. He developed abdominal pain followed by bloating and nausea as well as loose bowel movements. Soon he was having profuse watery diarrhea without odor. The stool is watery and white but the patient has no fever. Blood pressure is 95/62 lying down and drops to 75/40 standing. The skin turgor has reduced. HR is 110 and he looks ill with dry mucosa. V. cholerae was seen in dark-field microscopy of a fresh stool specimen. The lab study is as bellow: Sodium 137 meq/L Potassium 2 meq/L Chloride 94meq/L CO2 15 meq/L Fecal leukocytes None seen Fecal occult blood Negative

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Mycetoma 1. Subjects must meet all of the following to be eligible for enrollment into the study: 1. Subjects with eumycetoma caused by Madurella mycetomatis confirmed by PCR. 2. Eumycetoma lesion ≥ 2 cm and <10 cm in diameter 3. Single eumycetoma lesion present on the foot or lower limb 4. Age ≥18 years 5. Able to comply with protocol procedures and available for follow-up 6. Written informed consent from the subject 7. Female specific Negative pregnancy test If female of child bearing potential, using adequate contraception for the period of the trial to 2 months after completing study treatment 4.2  The presence of any of the following will a subject from study enrolment: 1. Previous surgical or medical treatment for eumycetoma which includes with any previous antifungal treatment 2. Presence of loco-regional lymphatic extension, osteomyelitis, other bone involvement based on radiology or any pre or co-existing condition that would preclude evaluation of the eumycetoma. 3. Pregnancy or lactation at screening, intent to become pregnant 4. Concomitant or severe diseases that may compromise the subject follow-up or evaluation (psychiatric condition, chronic hepatitis, neutropenia, or HIV/AIDS, diabetes mellitus, adrenocortical insufficiency for example) 5. Contraindication to the use of itraconazole including congestive heart failure, ventricular dysfunction, ventricular arrhythmia, negative inotropic state. For a comprehensive list of contraindications and contraindicated concomitant medication refer to the package insert for itraconazole (Sporanox®) 6. Contraindication to the use of fosravuconazole 7. Pre-existing liver disease, transaminase levels >2 x the laboratory's Upper Limit of Normal (ULN), or elevated levels of alkaline phosphatase or bilirubin 8. Receiving or likely to require drugs that are either a substrate for CYP3A4 and/or metabolized by CYP3A4 (cisapride, oral midazolam, nisoldipine, felodipine, pimozide, quinidine, dofetilide, triazolam, methadone, and levacetylmethadol [levomethadyl] are contraindicated) 9. Corrected QT by Fridericia's formula (QTcF) >450 msec on any ECG known about or taken prior to entry 10. Subjects with Familial Short QT syndrome or (corrected QT interval) QTc prolongation 11. History of hypersensitivity to any azole antifungal drug. 12. Participation in other clinical trials within a six-month period